Analysts at Bank of America began coverage on shares of ICON Public (NASDAQ:ICLR) in a research note issued to investors on Tuesday, The Fly reports. The firm set a “neutral” rating on the medical research company’s stock.
Several other equities analysts also recently issued reports on the stock. Wells Fargo & Company raised shares of ICON Public from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $200.00 to $235.00 in a research note on Thursday, April 1st. Barclays started coverage on ICON Public in a research report on Monday, March 8th. They set an “equal weight” rating and a $200.00 target price for the company. Zacks Investment Research lowered ICON Public from a “hold” rating to a “sell” rating in a research report on Thursday, February 25th. Robert W. Baird upgraded ICON Public from a “neutral” rating to an “outperform” rating and set a $215.00 price objective for the company in a research report on Monday, March 15th. Finally, Truist upgraded ICON Public from a “hold” rating to a “buy” rating and set a $280.00 target price on the stock in a report on Friday, February 26th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $218.27.
NASDAQ ICLR opened at $194.07 on Tuesday. The company has a market cap of $10.41 billion, a price-to-earnings ratio of 32.35, a price-to-earnings-growth ratio of 2.85 and a beta of 0.91. ICON Public has a twelve month low of $145.11 and a twelve month high of $223.62. The business’s fifty day moving average is $188.66 and its 200 day moving average is $196.63.
ICON Public (NASDAQ:ICLR) last posted its earnings results on Tuesday, February 23rd. The medical research company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.83 by $0.07. ICON Public had a return on equity of 21.42% and a net margin of 11.95%. The firm had revenue of $760.23 million during the quarter, compared to the consensus estimate of $750.16 million. During the same period last year, the company earned $1.83 earnings per share. The business’s quarterly revenue was up 4.8% on a year-over-year basis. Equities research analysts anticipate that ICON Public will post 6.45 EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Amundi Pioneer Asset Management Inc. lifted its stake in ICON Public by 2.1% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 24,400 shares of the medical research company’s stock valued at $3,332,000 after buying an additional 500 shares during the period. Sowell Financial Services LLC lifted its position in shares of ICON Public by 74.7% during the 4th quarter. Sowell Financial Services LLC now owns 255 shares of the medical research company’s stock valued at $50,000 after acquiring an additional 109 shares during the period. Fieldpoint Private Securities LLC boosted its stake in ICON Public by 11.4% during the fourth quarter. Fieldpoint Private Securities LLC now owns 1,237 shares of the medical research company’s stock worth $241,000 after acquiring an additional 127 shares in the last quarter. Kornitzer Capital Management Inc. KS grew its holdings in ICON Public by 1.7% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 84,766 shares of the medical research company’s stock worth $16,528,000 after purchasing an additional 1,400 shares during the period. Finally, Todd Asset Management LLC increased its stake in ICON Public by 18.6% in the fourth quarter. Todd Asset Management LLC now owns 103,487 shares of the medical research company’s stock valued at $20,177,000 after purchasing an additional 16,225 shares in the last quarter. 81.70% of the stock is owned by institutional investors and hedge funds.
About ICON Public
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development.
Further Reading: price-Sales Ratio
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: How a Strangle Strategy is different from a Straddle Strategy
7 Stocks It May Be Time To Take Profits On
Should you or shouldn’t you? Many investors are wondering if it’s time to take some profit. With so much uncertainty in the market, there can be a temptation to take your profits and run. That may or may not be a good strategy. It’s true there are some speculative stocks that are going up on nothing but faith, trust, and pixie dust. But there are other stocks that may still be good buys despite continuing to grow.
Since the sell-off caused by the novel coronavirus and subsequent locking down of large portions of the economy, the stock market has recovered nearly all of its losses. The Federal Reserve has done its part by pledging to keep interest rates low for as long as it takes. New housing starts are up. Unemployment is coming down. There seems to be a lot of fuel for market bulls.
Still, if you’ve been holding one of the stocks in this presentation, it may be time for you to take some of the profits you’ve made. Many of the stocks in this presentation are being downgraded by analysts. And that means that there is likely to be downward pressure on the stock price.
View the “7 Stocks It May Be Time To Take Profits On”.
See also Chase Online.
How to Send Money Online.
Partner Banking News.